1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
LungLife AI, Inc.

LungLife AI, Inc.

LLAI.L
LungLife AI, Inc.GB flagLondon Stock Exchange
4.15
GBp
-0.10
- -
1.27MMarket Cap
LungLife AI, Inc.
LLAI.L
(London Stock Exchange)

Recent

price

4.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
FRC
0.04
0.01
0.01
0.01
- -
- -
Revenue per Share
-0.13
-0.16
-0.19
-0.47
-0.3
-0.21
Basic EPS, GAAP
-0.08
-0.13
-0.11
-0.59
-0.23
-0.2
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.19
-2.36
-2.55
-4.54
-3.13
-3.34
Book Value per Share
-0.12
-0.27
-0.44
0.9
0.29
0.08
Tangible Book Value per Share
25
25
25
16
25
25
Basic Weighted Avg Shares
1
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-229.73
-2,499.93
-1,815.3
-2,740.51
-29,683.33
-12,560.87
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
-3
-4
-5
-7
-8
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-330.92
-3,060.76
-2,358.43
-3,817.44
-31,691.67
-11,767.39
Profit Margin (%)
-1
-7
-12
14
7
2
Working Capital
3
- -
- -
1
- -
- -
LT Debt
-3
-7
-11
20
13
8
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-33.39%
-39.78%
Free Cash Flow
- -
43.76%
-14.05%
Net Income, GAAP
- -
14.31%
-28.83%
Sales/Revenue/Turnover
- -
-7.35%
91.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-0.47
2022
- -
- -
- -
- -
-0.3
2023
- -
- -
- -
- -
-0.21

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Telo Genomics Corp. (TELO.V)
Instituto Hermes Pardini S.A. (PARD3.SA)
IQVIA Holdings Inc. (0JDM.L)
Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV)
Neuronetics, Inc. (STIM)
Telo Genomics Corp. (TDSGF)
Business
LungLife AI, Inc. develops advanced clinical diagnostic solutions for the early detection of lung cancer through artificial intelligence. The company's primary offering, the LungLB® test, is a blood-based diagnostic tool that utilizes machine learning and molecular analysis to identify circulating genetically abnormal cells. This innovative approach assists clinicians in evaluating indeterminate lung nodules, aiming to provide earlier and more precise information for patient management. The LungLB® test has demonstrated successful validation in multi-site clinical studies, particularly for smaller nodules, outperforming conventional methods by providing a strong positive predictive value. Operating from its CLIA-certified laboratory in Thousand Oaks, California, LungLife AI is currently exploring strategic partnerships for commercialization following shareholder approval in May 2025 to delist from AIM, as it navigates new funding avenues.